Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza

VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus June 18, 2014 Vertex Pharmaceuticals Incorporated today announced that it has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. for the worldwide development and commercialization of VX-787, a novel medicine discovered by Vertex for the treatment of influenza. As part …